We are live on ! Find out more
JANX icon

Janux Therapeutics
JANX

57 hedge funds and large institutions have $354M invested in Janux Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

500% more call options, than puts

Call options by funds: $24K | Put options by funds: $4K

50% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 6

44% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 16

6% more funds holding

Funds holding: 54 → 57 (+3)

3.16% more ownership

Funds ownership: 72.94% → 76.1% (+3.2%)

2% less capital invested

Capital invested by funds: $362M → $354M (-$8.13M)

Holders
57
Holders Change
+3
Holders Change %
+5.56%
% of All Funds
0.9%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
23
Reduced
16
Closed
6
Calls
$24K
Puts
$4K
Net Calls
+$20K
Net Calls Change
-$164K

Top Buyers

1
Citadel Advisors
Citadel Advisors
Florida
+$15.2M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$14.9M
3
RCM
RA Capital Management
Massachusetts
+$5.71M
4
O
OrbiMed
New York
+$5.55M
5
BI
BVF Inc
California
+$5.45M

Top Sellers

1
EC
EcoR1 Capital
California
-$5.37M
2
Cerity Partners
Cerity Partners
New York
-$723K
3
WP
Woodline Partners
California
-$595K
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$483K
5
Millennium Management
Millennium Management
New York
-$434K
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
RA Capital Management
Massachusetts
$92.4M +$5.71M +495,008 +6%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$64M +$14.9M +1,288,526 +25%
BI
3
BVF Inc
California
$46.2M +$5.45M +472,873 +12%
Citadel Advisors
4
Citadel Advisors
Florida
$34.6M +$15.2M +1,315,635 +62%
O
5
OrbiMed
New York
$33.4M +$5.55M +481,541 +17%
Janus Henderson Group
6
Janus Henderson Group
United Kingdom
$20.8M -$483K -41,870 -2%
BlackRock
7
BlackRock
New York
$16.5M +$5.13M +444,991 +37%
Adage Capital Partners
8
Adage Capital Partners
Massachusetts
$11.6M +$2.88M +250,000 +28%
Vanguard Group
9
Vanguard Group
Pennsylvania
$9.5M +$2.08M +180,291 +24%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$3.9M +$110K +9,579 +3%
SB
11
Samsara BioCapital
California
$3.63M – – –
State Street
12
State Street
Massachusetts
$3.34M -$11.8K -1,019 -0.3%
Northern Trust
13
Northern Trust
Illinois
$1.94M +$62.2K +5,395 +3%
Alyeska Investment Group
14
Alyeska Investment Group
Illinois
$1.76M +$2.02M +175,000 New
JP Morgan Chase
15
JP Morgan Chase
New York
$1.5M -$55.7K -4,827 -3%
Bank of Montreal
16
Bank of Montreal
Ontario, Canada
$1.08M +$1.14M +98,429 New
Millennium Management
17
Millennium Management
New York
$1.01M -$434K -37,634 -27%
WP
18
Woodline Partners
California
$864K -$595K -51,592 -38%
N
19
Nuveen
North Carolina
$672K +$91.8K +7,957 +14%
Bank of New York Mellon
20
Bank of New York Mellon
New York
$535K – – –
Charles Schwab
21
Charles Schwab
California
$491K +$30.3K +2,629 +6%
DekaBank Deutsche Girozentrale
22
DekaBank Deutsche Girozentrale
Germany
$484K – – –
Bank of America
23
Bank of America
North Carolina
$308K +$108K +9,393 +44%
RhumbLine Advisers
24
RhumbLine Advisers
Massachusetts
$267K -$2.84K -246 -0.9%
Renaissance Technologies
25
Renaissance Technologies
New York
$263K +$130K +11,300 +76%
1
2 3

JANX Hedge Fund Activity: Q3 2023 in Review

57 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q3 2023, worth a combined $354M — down 2.2% from $362M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new JANX positions and 6 closed out — a net gain of 3 holders — while 23 added to existing stakes and 16 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $15.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $5.37M sold.

  • 57 institutional investors held Janux Therapeutics (JANX) as of Q3 2023, up from 54 in Q2 2023.
  • Funds reported $354M of Janux Therapeutics stock for Q3 2023, down 2.2% quarter-over-quarter.
  • 9 funds opened new Janux Therapeutics positions in Q3 2023 and 6 closed out, a net change of +3 holders.
  • The largest Janux Therapeutics buyer in Q3 2023 was Citadel Advisors, an estimated $15.2M added.
  • The largest Janux Therapeutics seller in Q3 2023 was EcoR1 Capital, an estimated $5.37M sold.

Based on aggregated 13F filings for Q3 2023.